Roivant Sciences Ltd. Dividend History (ROIV)
Roivant Sciences Ltd. does not pay dividends currently 😔
They might in the future, check back soon!
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical company headquartered in Basel, Switzerland, and was founded in 2014 by Vivek Ramaswamy. Roivant stands out for its innovative business model focused on efficiently developing a diverse range of novel therapeutics through subsidiary companies known as "Vants." Each of these subsidiaries concentrates on specific therapeutic areas or technologies, enabling targeted and accelerated drug development. As of 2023, the CEO of Roivant Sciences is Matt Gline. The company has experienced significant growth and has formed numerous partnerships and collaborations to enhance its research and development capabilities. In 2023, Roivant reported substantial revenue, reflecting success in advancing several promising clinical programs. The company is well-regarded for its focus on addressing unmet medical needs and leveraging technology to streamline the drug development process.
Organon has completed the acquisition of Dermavant Sciences, a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology, including the FDA-approved VTAMA® (tapinarof) cream for the treatment of plaque psoriasis.
Benzinga · Published on Mon Oct 28 2024Roivant Sciences has agreed to sell its Dermavant Sciences subsidiary, which owns the rights to the psoriasis drug Vtama, to Organon for up to $1.2 billion. The transaction is expected to be modestly dilutive to Organon's Adjusted EBITDA in 2025 but turn accretive in 2026.
Benzinga · Published on Wed Sep 18 2024Organon, a global healthcare company, announced it will acquire Dermavant Sciences, a Roivant company, to expand its dermatology capabilities and gain access to VTAMA, an innovative topical therapy for plaque psoriasis and atopic dermatitis.
Benzinga · Published on Wed Sep 18 2024